Bevacizumab is used in
**Core Concept**
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), a key regulator of angiogenesis. By inhibiting VEGF-A, bevacizumab prevents the formation of new blood vessels, which is essential for tumor growth and metastasis.
**Why the Correct Answer is Right**
Bevacizumab is used in the treatment of various cancers, including colorectal, lung, breast, and renal cell carcinoma. It works by binding to VEGF-A, preventing its interaction with its receptor, and thereby inhibiting the signal transduction pathway that promotes angiogenesis. This leads to reduced tumor growth and progression. Bevacizumab is often used in combination with chemotherapy or other targeted therapies to enhance treatment efficacy.
**Why Each Wrong Option is Incorrect**
**Option A:** Bevacizumab is not primarily used in the treatment of autoimmune diseases, as its mechanism of action is focused on inhibiting angiogenesis, not modulating the immune system.
**Option B:** Bevacizumab is not a chemotherapy agent, but rather a targeted therapy that works by inhibiting angiogenesis, not by directly killing cancer cells.
**Option C:** Bevacizumab is not used in the treatment of infections, as its mechanism of action is focused on inhibiting tumor growth, not modulating the immune response to infections.
**Clinical Pearl / High-Yield Fact**
Bevacizumab is a good example of a targeted therapy that has revolutionized the treatment of various cancers by inhibiting angiogenesis, a key process in tumor growth and metastasis. This class of drugs has also led to the development of other targeted therapies that inhibit different pathways involved in cancer progression.
**Correct Answer:** C.